EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study

Remo Panaccione, Miguel Regueiro, Scott D Lee, Raja Atreya, Gitte Pedersen, Efrat Broide, Cristina Rodriguez, Adriaan A van Bodegraven, Elena Dubcenco, Ana P Lacerda, Tian Feng, Ziqian Geng und 4 weitere

Clinical Gastroenterology and Hepatology · 2026-03 · 24 (3) · 772-783

DOI: 10.1016/j.cgh.2025.07.028 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Remo Panaccione und 15 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Crohn Disease, Maintenance Chemotherapy, Janus Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Upadacitinib, an oral, reversible Janus kinase inhibitor, demonstrated efficacy and safety in patients with Crohn's disease in 2 phase III induction trials (U-EXCEL and U-EXCEED) and in a primary analysis of the first 502 patients entering the subsequent maintenance trial (U-ENDURE). Here, we present the overall results of the entire population of U-ENDURE (N = 673). METHODS: Clinical responders to 12 weeks of upadacitinib 45 mg once daily (QD) induction were randomized (1:1:1) to receive upadacitinib 15 mg QD (n = 221), upadacitinib 30 mg QD (n = 229), or placebo (n = 223) as maintenance therapy for 52 weeks. Coprimary endpoints were Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 52. Safety was assessed through week 52. RESULTS: At week 52, more upadacitinib-treated vs placebo patients achieved CDAI clinical remission (upadacitinib 15 mg, 36.2% and upadacitinib 30 mg, 51.5% vs placebo, 15.2%). The rates of endoscopic response were 27.3% for upadacitinib 15 mg and 40.7% for upadacitinib 30 mg vs 7.2% for placebo. Exposure-adjusted event rates for treatment-emergent adverse events were numerically lower with upadacitinib 15 mg and 30 mg vs placebo (351.3 and 324.5 per 100 patient-years, respectively, vs 462.8 per 100 patient-years) except for COVID-19 and adverse events leading to early discontinuation of study treatment. No deaths, active tuberculosis, lymphoma, nonmelanoma skin cancer, adjudicated major cardiovascular adverse events, or venous thromboembolic events were reported from any treatment group. Herpes zoster infections occurred more frequently in the upadacitinib groups compared with placebo; all were nonserious, and most involved a single dermatome. CONCLUSIONS: Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in patients with Crohn's disease. The safety profile remained consistent with no new safety signals. CLINICALTRIALS: gov Number: NCT03345823.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingCrohn DiseaseMaintenance ChemotherapyJanus Kinase InhibitorsHumansFemaleMaleAdultMiddle AgedTreatment OutcomeYoung AdultDouble-Blind Method

Stichwörter der Autor:innen

Crohn’s DiseaseEfficacyJanus Kinase InhibitorUpadacitinib

Substanzen

Heterocyclic Compounds, 3-RingupadacitinibJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
  • Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio.
  • Digestive Health Center, University of Washington Medical Center, Seattle, Washington.
  • First Department of Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
  • The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Assaf Harofeh Medical Center, Zerifin, Israel.

Förderung

  • AbbVie

Zitieren

APA

Panaccione, R., Regueiro, M., Lee, S. D., Atreya, R., Pedersen, G., Broide, E., Rodriguez, C., van Bodegraven, A. A., Dubcenco, E., Lacerda, A. P., Feng, T., Geng, Z., Wang, T., van Haaren, S., Anyanwu, S. I., & Panés, J. (2026). Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. Clinical Gastroenterology and Hepatology, 24(3), 772-783. https://doi.org/10.1016/j.cgh.2025.07.028

Vancouver

Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, et al. Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. Clinical Gastroenterology and Hepatology. 2026;24(3):772-783. doi:10.1016/j.cgh.2025.07.028

BibTeX
@article{Panaccione2026,
  author = {Panaccione, Remo and Regueiro, Miguel and Lee, Scott D and Atreya, Raja and Pedersen, Gitte and Broide, Efrat and Rodriguez, Cristina and van Bodegraven, Adriaan A and Dubcenco, Elena and Lacerda, Ana P and Feng, Tian and Geng, Ziqian and Wang, Tao and van Haaren, Stijn and Anyanwu, Samuel I and Panés, Julian},
  title = {Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {3},
  pages = {772--783},
  doi = {10.1016/j.cgh.2025.07.028}
}
Kostenlos starten →